2023
Disparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategies
2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assays